Investigational drug · Phase 3
cannabidiol as a clear that can be applied to the skin
Also called: ZYN002, transdermal delivery
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Fragile X Syndrome, Fragile X Syndrome (FXS).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "cannabidiol as a clear that can be applied to the skin"
First trial start
2021
Sep 13, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "cannabidiol as a clear that can be applied to the skin", any sponsor or status.
Conditions studied
As listed on its trial records.
- Fragile X Syndrome
- Fragile X Syndrome (FXS)
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "cannabidiol as a clear that can be applied to the skin" as an intervention, largest first.
- Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X SyndromePivotal-lookingCompleted
Harmony Biosciences Management, Inc.Industry
NCT04977986 · 257 participants · Start Sep 13, 2021 · Primary completion Aug 29, 2025
Drug: ZYN002; Placebo · For: Fragile X Syndrome; Fragile X Syndrome (FXS)
Sites: Phoenix, Arizona; Culver City, California; Irvine, California · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Microneedle-guided ultraviolet phototherapy with local calcipotriol delivery for enhanced psoriasis treatment.
Wang S, Zhang W, Zhao S, et al. · Biomaterials 2027
- Corrigendum to "Transdermal delivery of brucine-encapsulated liposomes significantly enhances anti-tumor outcomes in treating triple-negative breast cancer" [Biomater. Adv. 153 (2023) 213566].
Wu M, Hu Y, Xu M, et al. · Biomater Adv 2027
- Gas-propelled microneedles for precision transdermal therapeutics.
Xiao Z, Jia F, Wu W, et al. · Bioact Mater 2027
- Oxygen-enriching hollow MOF as nanobubbles to enhance treatment of hypertrophic scar via microneedle-mediated sonodynamic therapy.
Mu Y, Fu J, Wang Y, et al. · Biomaterials 2027
- Preparation and characterization of polydeoxyribonucleotide-poly(L-lysine) nanospheres with high penetration and hydrating properties for skin applications.
Hu W, Wu H, Zhao C, et al. · Colloids Surf B Biointerfaces 2027
- Hyaluronic acid-based selegiline nanostructured lipid carriers incorporated dissolving microneedles: A localised transdermal delivery strategy for obesity management.
Purkait P, Jose J, Aswani N, et al. · Colloids Surf B Biointerfaces 2027
Also in development for Fragile X Syndrome
- BPN14770zatolmilastPhase 34 trials
Tetra Discovery Partners · Fragile X Syndrome, Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
- SPG601CodabakalnerPhase 32 trials
Spinogenix · Fragile X Syndrome (FXS), Autism Spectrum Disorder (ASD), Fragile X Syndrome
- CTH120Phase 21 trial
Connecta Therapeutics, S.L. · Fragile X Syndrome (FXS), Fragile X Syndrome
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.